



Dr. Jörg Ritter

Partner

Munich

T +49 89 38398 0220

E jritter@orrick.com

Practice Areas

- Technology Companies Group
- Mergers & Acquisitions
- Funds
- International Tax

Education

- Dr. jur., University of Bayreuth, Faculty of Law, 1997, *magna cum laude*
- Second State Examination, University of Munich, 1995
- First State Examination, University of Bayreuth, 1993

Memberships

- Board Member of Karl & Wilhelm Maybach Family Foundation, Stuttgart and San Francisco
- Verband der Fachanwälte für Steuerrecht (German Association of Tax Lawyers)
- Gesellschaft für internationales Erb- und Erbschaftsteuerrecht (Association of International Estate and Estate Tax Law)
- Munich Bar Association

Jörg Ritter, a partner in the Munich office, is a member of the Corporate Group. He focuses his practice on mergers and acquisitions, venture capital and private equity investments, corporate litigation, German and international tax law and bankruptcy law.

Jörg represents clients in all types of corporate transactions and litigation, including international venture capital and private equity funds as well as a variety of family offices.

Prior to joining Orrick, Jörg was a partner in the Munich office of an international U.S.-headquartered law firm.

Representative Engagements

- More than 250 M&A-, Private Equity- and Venture Capital-Transactions.
- Extensive experience in legal disputes, in particular shareholder disputes and management liability cases
- Comprehensive experience as party appointed arbitrator (*Schiedsrichter*)
- Advising the PHW Group on the sale of Lohmann SE to Eli Lilly
- Advising the Maybach Family on the sale of MTU Friedrichshafen to Daimler AG / EQT
- Consulting the stakeholders of iTAC Software AG for sale to Dürr AG, including TVM, PariGroup, SAP Ventures
- Advising the stakeholders of Definiens AG on sale to AstraZeneca
- Advising on the structuring and integration of Europe's largest solar power plant

Publications

- Die verborgenen Lücken des Freigabeverfahrens - Warum der Gesetzgeber jetzt tätig werden muss“ (veröffentlicht zusammen mit S. Meul in Die Aktiengesellschaft - AG, Heft 23/2017, 5. Dezember 2017, S. 841)
- § 9b Abs. 1 GmbHG - Freifahrtschein oder Beschränkung für den Insolvenzverwalter?“ (veröffentlicht zusammen mit S. Meul

in Neue Zeitschrift für Insolvenzrecht - NZI, Heft 18, 6. September 2017, S. 689)

- Grundsätze der Scharia/Bedeutung für Biotech-Investitionen in der MENA-Region, Going Public Magazine 10 /10
- Haftung des Managements/Die D&O-Versicherung in der Insolvenz, Going Public Magazine 09 / 09
- Unterschiede zwischen USA und Europa/Neueste Entwicklungen der Biotech-Branche, Going Public Magazine 09 / 08
- PIPEs auf dem Weg nach Deutschland/Finanzierungsalternative für börsennotierte Biotechunternehmen, Going Public Magazine 09 / 07
- Am Anfang steht die Exitstrategie - Die Bedeutung der Desinvestitionsstrategie für die Investitionsentscheidung, Going Public Magazine 09 / 06
- Co-author in Münchener Anwaltshandbuch Erbrecht, 3rd ed.

Languages

- German
- English
- French
- Italian

Admissions

- Germany